A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer

被引：0
作者：
Gary H. Lyman
Stephanie J. Green
Peter M. Ravdin
Charles E. Geyer
Christy A. Russell
Stanley P. Balcerzak
G. Thomas Budd
Silvana Martino
机构：
[1] University of Rochester Medical Center,James P. Wilmot Cancer Center
[2] University of Rochester School of Medicine,undefined
[3] Strong Memorial Hospital,undefined
[4] Southwest Oncology Group Statistical Center,undefined
[5] University of Texas Health Science Center,undefined
[6] University of Southern California,undefined
[7] Ohio State University,undefined
[8] Cleveland Clinic,undefined
[9] John Wayne Cancer Institute,undefined
来源：
Breast Cancer Research and Treatment | 2004年 / 85卷
关键词：
doxorubicin; metastatic breast cancer; paclitaxel; phase II; SWOG;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose. To evaluate whether the high complete response (CR) rates for the combination of doxorubicin and paclitaxel in metastatic breast cancer observed in two European studies could be replicated in a multi-institutional cooperative group trial.
引用
收藏
页码：143 / 150
页数：7
相关论文
共 50 条
  • [41] A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer
    Silverio Tomao
    Adriana Romiti
    Federica Tomao
    Marisa Di Seri
    Giuliana Caprio
    Gian Paolo Spinelli
    Edmondo Terzoli
    Luigi Frati
    [J]. BMC Cancer, 6
  • [42] Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group
    Scudder, SA
    Liu, PY
    Wilczynski, SP
    Smith, HO
    Jiang, C
    Hallum, AV
    Smith, GB
    Hannigan, EV
    Markman, M
    Alberts, DS
    [J]. GYNECOLOGIC ONCOLOGY, 2005, 96 (03) : 610 - 615
  • [43] Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy
    Lalisang, R. I.
    Erdkamp, F. L. G.
    Rodenburg, C. J.
    Knibbeler-van Rossum, C. T. A. M.
    Nortier, J. W. R.
    van Bochove, A.
    Slee, P. H. Th. J.
    Voest, E. E.
    Wils, J. A.
    Wals, J.
    Loosveld, O. J. L.
    Smals, A. E. M.
    Blijham, G. H.
    Tjan-Heijnen, V. C. G.
    Schouten, H. C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (02) : 437 - 445
  • [44] Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer
    Bourgeois, Hugues
    Ferru, Aurelie
    Lortholary, Alain
    Delozier, Thierry
    Boisdron-Celle, Michelle
    Abadie-Lacourtoisie, Sophie
    Joly, Florence
    Chieze, Stephanie
    Chabrun, Virginie
    Gamelin, Erick
    Tourani, Jean-Marc
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (03): : 267 - 275
  • [45] A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
    Fornier, M. N.
    Morris, P. G.
    Abbruzzi, A.
    D'Andrea, G.
    Gilewski, T.
    Bromberg, J.
    Dang, C.
    Dickler, M.
    Modi, S.
    Seidman, A. D.
    Sklarin, N.
    Chang, J.
    Norton, L.
    Hudis, C. A.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (12) : 2575 - 2581
  • [46] Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure
    Demiray, M
    Kurt, E
    Evrensel, T
    Kanat, O
    Arslan, M
    Saraydaroglu, O
    Ercan, K
    Gonullu, G
    Gokgoz, S
    Topal, U
    Tolunay, S
    Tasdelen, I
    Manavoglu, O
    [J]. CANCER INVESTIGATION, 2005, 23 (05) : 386 - 391
  • [47] Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a Phase II study
    Rigatos, SK
    Tsavdaridis, D
    Athanasiadis, A
    Stathopoulos, JG
    Stathopoulos, GP
    [J]. ONCOLOGY REPORTS, 2003, 10 (06) : 1817 - 1819
  • [48] Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study
    Tanaka, Maki
    Takamatsu, Yasushi
    Anan, Keisei
    Ohno, Shinji
    Nishimura, Reiki
    Yamamoto, Yutaka
    Masuda, Norikazu
    Mitsuyama, Shoshu
    Tamura, Kazuo
    [J]. ANTI-CANCER DRUGS, 2010, 21 (04) : 453 - 458
  • [49] A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
    Dimitrios Bafaloukos
    Helena Linardou
    Gerasimos Aravantinos
    Christos Papadimitriou
    Aristotelis Bamias
    George Fountzilas
    Haralabos P Kalofonos
    Paris Kosmidis
    Eleni Timotheadou
    Thomas Makatsoris
    Epaminondas Samantas
    Evangelos Briasoulis
    Christos Christodoulou
    Pavlos Papakostas
    Dimitrios Pectasides
    Athanasios M Dimopoulos
    [J]. BMC Medicine, 8
  • [50] First line therapy with paclitaxel (Taxol®) and pegylated liposomal doxorubicin (Caelyx®) in patients with metastatic breast cancer:: a multicentre phase II study
    Vorobiof, DA
    Rapoport, BL
    Chasen, MR
    Slabber, C
    McMichael, G
    Eek, R
    Mohammed, C
    [J]. BREAST, 2004, 13 (03) : 219 - 226
12345